


Epilepsy in Children and Adolescents

EDITED BY

James W. Wheless

David F. Clarke, Amy L. McGregor, Phillip L. Pearl and Yu-Tze Ng



 WILEY-BLACKWELL

Contents

[Cover](#)

[Title Page](#)

[Copyright](#)

[List of contributors](#)

[Preface](#)

[Section 1: Epidemiology and classification of childhood epilepsies](#)

[Chapter 1: Epidemiology and common comorbidities of epilepsy in childhood](#)

[1.1 Epidemiology](#)

[1.2 Incidence and prevalence](#)

[1.3 Gender and age](#)

[1.4 Classification](#)

[1.5 Febrile seizures](#)

[1.6 Etiology](#)

[1.7 Psychiatric comorbidity](#)

[1.8 Psychological and psychosocial stress related to chronic disease](#)

[1.9 Psychiatric symptoms related to medication side effects](#)

[1.10 Psychiatric comorbidity related to epilepsy pathophysiology](#)

[1.11 Attention-deficit/hyperactivity disorder \(ADHD\)](#)

[1.12 Anxiety](#)

[1.13 Depression](#)

[1.14 Intellectual and developmental disabilities \(IDD\)](#)

[1.15 Conclusion](#)

[References](#)

[Chapter 2: Classification and definition of seizures and epilepsy syndromes in childhood](#)

[2.1 Introduction](#)

[2.2 Purpose and goals of definitions and classification](#)

[2.3 Systems of classification and definitions](#)

[2.4 Seizures](#)

[2.5 Generalized seizures](#)

[2.6 Focal seizures](#)

[2.7 Syndromes](#)

[2.8 Specific age-related epilepsy syndromes](#)

[2.9 Future directions](#)

[2.10 Acknowledgements](#)

[References](#)

Chapter 3: Initiating and withdrawing medical management

3.1 Initiating medical management

3.2 The chances of seizure recurrence after the first unprovoked seizure

3.3 Seizure recurrence

3.4 The possible adverse effects of seizure recurrence

3.5 The risks of initiating antiepileptic drug therapy

3.6 The benefits of initiating antiepileptic drug therapy

3.7 How to initiate treatment with antiepileptic drugs

3.8 Special circumstances

3.9 Summary: initiating medical management

3.10 Withdrawing medical management

3.11 The long-term prognosis of childhood-onset epilepsy

3.12 When to consider discontinuing antiepileptic drug therapy

3.13 Risk factors for seizure recurrence after discontinuation

3.14 The risks of discontinuing antiepileptic drug therapy

3.15 The benefits of discontinuing antiepileptic drug therapy

3.16 How to discontinue antiepileptic drugs

3.17 Special circumstances

[3.18 Summary: withdrawing medical management](#)

[3.19 Disclaimer](#)

[References](#)

[Chapter 4: Common genetic and neurocutaneous disorders in childhood epilepsy](#)

[4.1 Idiopathic epilepsies](#)

[4.2 Symptomatic epilepsies](#)

[4.3 Epilepsy in common chromosomal abnormalities](#)

[4.4 Epilepsy in metabolic and mitochondrial disorders](#)

[4.5 Epilepsy in malformations of cortical development](#)

[4.6 Neurocutaneous disorders](#)

[4.7 Summary](#)

[References](#)

[Section 2: Diagnostic evaluation of childhood epilepsies](#)

[Chapter 5: Evaluating the child with seizures](#)

[5.1 Emergent diagnosis and management](#)

[5.2 Subsequent evaluation](#)

[5.3 Additional neurodiagnostic evaluation](#)

References

Chapter 6: The use of EEG in the diagnosis of childhood epilepsy

6.1 Technical aspects of the EEG

6.2 Methods used to increase EEG yield

6.3 When should an EEG be ordered?

6.4 EEG findings in epilepsy and epilepsy syndromes

6.5 Neonatal EEGs

6.6 The EEG in focal epilepsy

6.7 The EEG of generalized epilepsy

6.8 Specific disease-related epilepsy syndromes

6.9 Conclusion

References

Chapter 7: Imaging of pediatric epilepsy

7.1 Introduction

7.2 Imaging considerations

7.3 Congenital malformations

7.4 Neoplasms

7.5 Acquired/idiopathic abnormalities

References

Chapter 8: Non-epileptic paroxysmal events of childhood

8.1 Introduction

8.2 Breath-holding spells

8.3 Parasomnias

[8.4 Benign paroxysmal positional vertigo of childhood](#)

[8.5 Syncope](#)

[8.6 Paroxysmal non-epileptic events \(PNEs\) with a psychiatric or behavioral basis](#)

[8.7 Hyperekplexia](#)

[8.8 Alternating hemiplegia of childhood](#)

[8.9 Movement disorders](#)

[8.10 Sandifer syndrome](#)

[8.11 Conclusion](#)

[References](#)

[Section 3: Principles of treatment](#)

[Chapter 9: Pharmacology of antiepileptic drugs](#)

[9.1 Pharmacokinetics](#)

[9.2 Pharmacogenomics](#)

[References](#)

[Chapter 10: Therapeutic efficacy of antiepileptic drugs](#)

[10.1 Efficacy-based treatment guidelines](#)

[10.2 Antiepileptic drug selection based on specific pediatric epilepsy syndromes](#)

[10.3 Influence of comorbidities in children with epilepsy](#)

[10.4 Conclusions](#)

[References](#)

Chapter 11: Adverse effects of antiepileptic drugs

11.1 Introduction

11.2 Specific drugs

11.3 At-risk profiles and monitoring

References

Chapter 12: Vagus nerve stimulation therapy and epilepsy surgery

12.1 Vagus nerve stimulation

12.2 Epilepsy surgery

12.3 Conclusions

References

Chapter 13: Dietary therapies to treat epilepsy

13.1 History

13.2 Efficacy

13.3 Mechanism of action

13.4 Selection of candidates for the diet

13.5 Initiation and maintenance

13.6 Complications

13.7 The ketogenic diet in the twenty-first century

References

Resources

Websites

Section 4: Generalized seizures and generalized epilepsy syndromes

Chapter 14: Idiopathic generalized epilepsies

14.1 Clinical features

14.2 Natural history

14.3 Genetics

14.4 Treatment

14.5 Classification

14.6 Myoclonic epilepsy in infancy

14.7 Childhood absence epilepsy (CAE)

14.8 Juvenile absence epilepsy (JAE)

14.9 Juvenile myoclonic epilepsy (JME)

14.10 Epilepsy with generalized tonic-clonic seizures alone (IGE-GTCs)

14.11 Epilepsy with myoclonic absence

14.12 Epilepsy with myoclonic-atonic seizures/Doose syndrome

14.13 Febrile seizures plus (FS+)

14.14 Eyelid myoclonia with absences (EMA)/Jeavons syndrome

14.15 Summary

References

Chapter 15: Cryptogenic and symptomatic generalized epilepsies: epilepsies with encephalopathy

[15.1 Neonatal-onset epilepsies with encephalopathy](#)

[15.2 Infantile-onset epilepsies with encephalopathy](#)

[15.3 Epilepsies with encephalopathy with onset later in infancy](#)

[15.4 Epilepsies with encephalopathy with onset after infancy](#)

[15.5 Continuous spike wave of sleep \(CSWS\) and Landau-Kleffner syndrome \(LKS\)](#)

[References](#)

[Section 5: Partial-onset seizures and localization-related epilepsy syndromes](#)

[Chapter 16: Idiopathic partial epilepsies](#)

[16.1 Benign infantile seizures](#)

[16.2 Benign childhood epilepsy with centrotemporal spikes](#)

[16.3 Childhood occipital epilepsy \(Panayiotopoulos type\)](#)

[16.4 Late-onset childhood occipital epilepsy \(Gastaut type\)](#)

[References](#)

[Chapter 17: Cryptogenic and symptomatic partial epilepsies](#)

[17.1 Etiology](#)

[17.2 Seizure phenomena](#)
[17.3 Temporal lobe epilepsy](#)
[17.4 Extratemporal epilepsy](#)
[17.5 Occipital lobe epilepsy](#)
[17.6 Parietal lobe epilepsy](#)
[17.7 Hypothalamic hamartoma](#)
[17.8 Other localizing and lateralizing signs](#)
[References](#)

[Section 6: Epilepsies relative to age, etiology, or duration](#)

[Chapter 18: Neonatal seizures](#)

[18.1 Significance of neonatal seizures](#)
[18.2 Pathophysiology of neonatal seizures](#)
[18.3 Classification and clinical features of neonatal seizures](#)
[18.4 Electrographic seizures](#)
[18.5 Monitoring and recording](#)
[18.6 Etiology of neonatal seizures](#)
[18.7 Metabolic causes for neonatal seizures](#)
[18.8 Inborn errors of metabolism](#)
[18.9 Treatment](#)
[18.10 Chronic postnatal epilepsy and the need for long-term treatment](#)
[18.11 Potential adverse effects of antiepileptic drugs on the immature CNS](#)
[18.12 Conclusion](#)
[References](#)

Chapter 19: Febrile seizures

19.1 Introduction

19.2 Definition

19.3 Incidence and prevalence

19.4 Pathophysiology

19.5 Prognosis

19.6 Initial evaluation and management

19.7 Long-term management

19.8 Management in practice

19.9 Genetics

19.10 Parent counseling

19.11 Conclusion

References

Chapter 20: Status epilepticus in childhood

20.1 Definition

20.2 Epidemiology

20.3 Pathophysiology

20.4 Etiology

20.5 Diagnosis and investigations

20.6 EEG patterns in status epilepticus

20.7 Treatment

20.8 Prognosis

References

Index

Epilepsy in Children and Adolescents

Edited by

James W. Wheless, MD

Department of Pediatric Neurology

University of Tennessee Health Science Center

Le Bonheur Comprehensive Epilepsy

Program and Neuroscience Institute

Le Bonheur Children's Hospital

Memphis, TN, USA



WILEY-BLACKWELL

A John Wiley & Sons, Ltd., Publication

This edition first published 2013 © 2013 by John Wiley & Sons, Ltd

Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wiley's global Scientific, Technical and Medical business with Blackwell Publishing.

Registered office: John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Editorial offices: 9600 Garsington Road, Oxford, OX4 2DQ, UK

The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell.

The right of the author to be identified as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the

understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by physicians for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

Library of Congress Cataloging-in-Publication Data

Epilepsy in children and adolescents / [edited by] James W. Wheless.

p.; cm.

Includes bibliographical references and index.

ISBN 978-0-470-74123-8 (cloth)

I. Wheless, James.

[DNLM: 1. Epilepsy. 2. Adolescent. 3. Anticonvulsants-therapeutic use. 4. Child. 5. Epilepsy-therapy. WL 385]

616.85'300835-dc23

2012024368

A catalogue record for this book is available from the British Library.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

List of contributors

Matthew Byrne, BA

Uniformed Services
University of the Health Sciences
Bethesda, MD
USA

Asim F. Choudhri, MD

Departments of Radiology and Neurosurgery
University of Tennessee Health Science Center
Le Bonheur Children's Hospital
Memphis, TN
USA

Dave Clarke, MBBS, ABPN (Child Neurology and Sleep), ABCN

Dell Children's Comprehensive Epilepsy Program
Dell Children's Medical Center of Central Texas
Austin, TX
USA

Susan E. Combs, MD

Department of Neurology
Children's National Medical Center
The George Washington University School of Medicine
Washington, DC
USA

Dewi Frances T. Depositario-Cabacar, MD

Neurology and Pediatrics
George Washington University Medical Center
Children's National Medical Center

Washington, DC
USA

Georgann Ferrone, MD

Center for Neuroscience and Behavioral Medicine
Children's National Medical Center
Washington, DC
USA

Stephen Fulton, MD

Department of Neurology and Pediatrics
University of Tennessee Health Science Center
LeBonheur Comprehensive Epilepsy Program
Le Bonheur Children's Hospital
Memphis, TN
USA

Marie Francisca Grill, MD

Department of Neurology
University of California San Francisco
San Francisco General Hospital
San Francisco, CA
USA

Eric V. Hastriter, MD

Mayo Clinic Hospital
Phoenix, AZ
USA

David T. Hsieh, MD

San Antonio Military Medical Center
Division of Child Neurology
Wilford Hall Medical Center
Lackland AFB, TX
USA

Sucheta M. Joshi, MD, MS

Pediatrics and Communicable Diseases
Division of Pediatric Neurology
University of Michigan
Ann Arbor, MI
USA

Karen Keough, MD

'Specially For Children'
Austin, TX
USA

Susan Koh, MD

Children's Hospital Colorado
Aurora, CO
USA

Rama Maganti, MD

Department of Neurology
Barrow Neurological Institute
St Joseph's Hospital and Medical Center
Phoenix, AZ
USA

William McClintock, MD

Neurology and Pediatrics
George Washington University Medical Center
Children's National Medical Center
Washington, DC
USA

Amy McGregor, MD

Department of Pediatrics
Division of Child Neurology

Le Bonheur Comprehensive Epilepsy Program
University of Tennessee Health Science Center
Memphis, TN
USA

Bhagwan Indur Moorjani, MD, FAAP, FAAN
Hope Neurologic Center, La Quinta
JFK Memorial Hospital
Indio, CA
USA

Yu-tze Ng, MD, FRACP
University of Oklahoma
Health Science Center and The Children's Hospital
Pediatric Neurology
Oklahoma city, OK
USA

Kristen Park, MD
Children's Hospital Colorado
Aurora, CO
USA

Phillip L. Pearl, MD
Department of Neurology
Children's National Medical Center
The George Washington University School of Medicine
Washington, DC
USA

Freedom F. Perkins Jr, MD
Seton Healthcare and Dell Children's Hospital
Austin, TX
USA

Tom Reehal, BA

University of Sheffield School of Medicine
Dentistry and Health
Sheffield
UK

Jay Salpekar, MD

Center for Neuroscience and Behavioral Medicine
Children's National Medical Center
Washington, DC
USA

Kate Van Poppel, MD

Department of Pediatric Neurology
University of Tennessee Health Science Center
Le Bonheur Comprehensive Epilepsy Program and
Neuroscience Institute
Le Bonheur Children's Hospital
Memphis, TN
USA

James W. Wheless, MD, FAAP, FACP, FAAN

Department of Pediatric Neurology
University of Tennessee Health Science Center
Le Bonheur Comprehensive Epilepsy Program and
Neuroscience Institute
Le Bonheur Children's Hospital
Memphis, TN
USA

Preface

Of all the neurological disorders that affect infants, children, and adolescents, epilepsy is a profound challenge for the patients, caregivers, and physicians and demands expertise to evaluate and treat. As with every illness, gathering a clinical history is an important first step in helping define the problem. However, remarkable improvements in our ability to image brain structures, define physiological patterns, and select medications has made the task of caring for the child with epilepsy more effective than in past years. I envision this book to be a resource for all physicians and other professionals taking care of children with seizures or epilepsy. The goal was for each chapter to be succinct, so a physician confronted with a child who has seizures would have an efficient resource for answering questions and designing treatment. I thank the authors for their focus and persistence. I am ever mindful of the patients and their families who bear the challenge of epilepsy with courage. I have learned from them and am keenly aware of our responsibility to do the very best for their care.

James W. Wheless
Memphis, TN, USA
June, 2012

Section 1

Epidemiology and classification of childhood epilepsies

Phillip L. Pearl

1

Epidemiology and common comorbidities of epilepsy in childhood

Jay Salpekar¹, Matthew Byrne² and Georgann Ferrone¹

¹Center for Neuroscience and Behavioral Medicine,
Children's National Medical Center, Washington, DC, USA

²Uniformed Services University of the Health Sciences,
Bethesda, MD, USA

Epilepsy is a common illness in childhood, and the epidemiology has been well described. However, epilepsy is also complex and controversial in terms of optimal methods for diagnosis and treatment. Classification schemes for seizures have been refined over the years and improved treatment options have allowed better outcomes for children with epilepsy. Understanding of comorbidity, particularly psychiatric comorbidity, has also improved over recent years, yet in many cases it is difficult to resolve whether psychiatric illness is coincidental or associated with the underlying seizure disorder. This chapter addresses the incidence and prevalence of childhood epilepsy and strategies for identifying and managing common psychiatric comorbidities.

1.1 Epidemiology

An epileptic seizure is defined as the clinical manifestation of abnormal or excessive discharge of neurons in the brain [1]. Epilepsy is defined as recurrent seizures, specifically two or more seizures separated by 24 hours but within 18 months of one another [1,2]. This common consensus is based on observations that children who experience one seizure have an approximately 50% chance of recurrence within 2 years [3,4]. It is important to note that febrile seizures are not included in most epidemiological studies of epilepsy.

Population-based studies concerning seizures and epilepsy have been done in numerous communities around the world. Although many international studies of prevalence are based on small communities, the results can be extrapolated to reflect wider regions of the world. In the United States, there are approximately 2.3 million people diagnosed with epilepsy, which reflects an incidence of approximately 1% of the population [5]. The pediatric population, however, has a higher prevalence of epilepsy; 4–10% of children will experience a seizure before the age of 16. Thus, a working knowledge of epilepsy is very important for primary and specialty clinicians in pediatrics, as well as for pediatric neurologists [6].

Terminology review

Incidence: The rate at which new cases of disease occur in a population during a given period of time.

Prevalence: The proportion of a population who have a disease during a given time period.

1.2 Incidence and prevalence

In the general population, the incidence of epilepsy is reported at between 40 and 70 cases per 100 000 [7]. The incidence of childhood epilepsy has been reported to be

82.2 per 100 000 children, markedly higher than that of the overall population [8]. A meta-analysis of over 40 epidemiological studies found that the highest incidence of epilepsy occurs in childhood and in the geriatric population. Interestingly, the incidence of epilepsy has been decreasing over the past 50 years. This decrease in incidence could be explained by more stringent and/or universally followed diagnostic criteria or perhaps from a decrease in exposure to epilepsy risk factors [8].

The overall number of children affected by epilepsy, or the prevalence of the disease, is higher than the incidence because of the chronic nature of epilepsy. A significant variation in prevalence is found in international epidemiology studies [9-12]. In the United States, epilepsy prevalence averages 3.83 per 1000 children, while in northern Tanzania, it is 7.39 per 1000 [13,14]. This discrepancy may result from a variety of factors including possible misclassification of a single seizure as epilepsy. Environmental factors, access to healthcare, and different methods of reporting may also account for some of the variability. The prevalence of epilepsy in varying regions across the world is described in [Table 1.1](#).


[Table 1.1](#) International epidemiology studies.

Location	Years of study	Epilepsy prevalence	Age range	Limits/comments
Okayama Prefecture, Japan [9]	1999	5.3 per 1000	0–12 years	Removed data resulting from only one seizure
Kayenta, Shiprock, and Crowpoint Reservations, Navajo Nation, USA [10]	1999–2002	6.46 per 1000	0–19 years	Only those who went to hospital; excluded those who used tribal medicine
Hordaland count, western Norway [12]	1995	5.13 per 1000	6–12 years	Small sample area, limited age range
Northern Tanzania (14)	2003–2004	7.39 per 1000	0–19 years	Only villages polled around centralized hospital location
Rochester, Minnesota [13]	1950–1980	3.83 per 1000	0–14 years	Very comprehensive
Estonia [15,16]	1995–1997	3.7 per 1000	0–19 years	Much of data came from one hospital, University of Tartu
Canada [17]	1994–2001	2.5 per 1000	0–11 years	Utilized national census data
		4.4 per 1000	12–14 years	

1.3 Gender and age

Studies have consistently found that males are diagnosed with epilepsy more often than females [18]. While the difference between the genders is slight, this trend holds true for most populations [13]. Although there are exceptions to this trend, they are rarely statistically significant in children [10,11]. Analysis of prevalence among children of varying ages found that epilepsy was most common in children under the age of 5, with a gradual decline in occurrence in older age groups [15]. [Figure 1.1](#) demonstrates the peak of prevalence at a young age and a gradual decrease in children as they age.

[FIGURE 1.1](#) Graph showing prevalence of epilepsy (per 1000) in children by year from age 1 to 19 [16].




1.4 Classification

When studying the epidemiology of epilepsy, means of classification must be clarified to ensure uniformity in standards. Since 1909, the International League Against Epilepsy (ILAE) has worked toward identifying, studying, and classifying all variations of seizure disorders. Epilepsy syndromes can be classified as localization-related or generalized. The syndromes are determined by multiple criteria, with particular emphasis on seizure type as well as associated patient characteristics such as age of onset, comorbidities including neurodevelopmental status, presence of associated family history, and identification of an underlying etiology [1]. Distinguishing characteristics of seizure types can range from loss or modification of consciousness and responsiveness, along with total or partial motor control impairment [2].

A 40-year detailed study done in Rochester, Minnesota, found that partial seizures are the most prevalent, followed by generalized tonic-clonic, absence, and then myoclonic. Details for prevalence are represented in [Figure 1.2](#) [13].

FIGURE 1.2 Bar graph of relative prevalence of adolescent seizure etiologies (per 1000) [13].



1.5 Febrile seizures

Febrile seizures are a common seizure disorder for children under the age of 3 years. Between 2% and 4% of children will suffer from one febrile seizure, and only one-third of these children will have a second seizure [18]. Most importantly, a febrile seizure will not always lead to epilepsy. Between 2% and 10% of children who experience one febrile seizure will develop epilepsy [19].

1.6 Etiology

Most cases of epilepsy are of unknown etiology [12]. Recent guidelines have identified three main classifications of epilepsy etiologies: Genetic, metabolic/structural, and idiopathic/unknown [2]. Genetic disorders include diseases

due to a known genetic defect in which seizures are the main manifestation of the disease. Seizures of metabolic/structural etiology can be those epilepsies attributed to lesions, which are often a result of head trauma, central nervous system (CNS) infection, or tumor [4]. Epilepsy of unknown etiology represents the most common designation for epilepsy in childhood.

1.7 Psychiatric comorbidity

Psychiatric and psychological complications are commonly associated with pediatric epilepsy [20-23]. In pediatrics, the classic Isle of Wight epidemiology study reports psychiatric illness present in 16% of patients with chronic medical illness; however, if that illness happened to be epilepsy, the psychiatric comorbidity was 29% [24]. Subsequent studies have confirmed an overrepresentation of psychiatric illness associated with epilepsy as compared to many other chronic medical illnesses. Some studies report a two- or three-fold greater prevalence of psychiatric illness associated with epilepsy as compared to diabetes or asthma [25,26]. Of particular concern is evidence showing an overrepresentation of epilepsy among children and adolescents hospitalized for suicide attempts [27]. Despite numerous reports confirming high levels of comorbidity, many children and adolescents with epilepsy do not receive treatment for psychiatric illness [28]. In many cases, the psychiatric comorbidity may be more impairing to quality of life for children and families than the seizures themselves [29].

This consistently high level of psychiatric comorbidity suggests that epilepsy is a complicated illness that may have neuropsychiatric symptoms well beyond discrete seizures. However, the etiology of psychiatric comorbidity in children and adolescents with epilepsy is still controversial.